# A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

> **NCT07093814** · PHASE1,PHASE2 · RECRUITING · sponsor: **Guangzhou Virotech Pharmaceutical Co., Ltd.** · enrollment: 42 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** VRT106

## Key facts

- **NCT ID:** NCT07093814
- **Lead sponsor:** Guangzhou Virotech Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-02
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-06-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07093814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07093814, "A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07093814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*